Just in the first ten days of the brand-new year – 2019, three important oncology focused acquisitions were announced by three top global pharma companies. On January 03, 2019, Bristol-Myers Squibb announced that it will acquire Celgene for a hefty sum of USD … Continue reading
Tag Archives: drivers
Increasing Consumerism: A Prime Mover For Change in Healthcare
Increasing ‘consumerism’ has already become a strong prime mover to reckon with, even in healthcare, including the pharma industry, across the world. Patients’ longing for better participative treatment experience at an affordable cost, has started gathering momentum as a major disrupting … Continue reading
Key Drivers And Long-Term Impact of Pharma M&A in India
Corporate M&A is increasingly considered an integral part of the organization’s growth strategy for value creation, by a large number of pharma companies, across the world. In tandem, it throws open many other doors of opportunities, such as reduction of … Continue reading
Is The Global Generic Drug Market Slowing Down?
Driven by a strong environmental headwind, both within and outside the country, several pharma companies in India have recently started raising a red flag on their future earning guidance for the stock market, though citing quite different reasons altogether. Quoting … Continue reading
Biosimilar Drugs: First Indian Foot Print In An Uncharted Frontier
A homegrown Indian biologic manufacturer is now about to leave behind its first foot-print, with a ‘made in India’ biosimilar drug, in one of the largest pharma market of the world. This was indeed an uncharted frontier, and a dream … Continue reading
Biosimilar Drugs: Why Prescriptions Aren’t Still Enough?
On September 3, 2015, in a Press Release, Novartis announced, “Zarxio(TM) (filgrastim-sndz) is now available in the United States. Zarxio is the first biosimilar approved by the US Food and Drug Administration (FDA) and the first to launch in the … Continue reading
Pharma Outlook 2015: A Glimpse Of Some Drivers and Barriers
Looking ahead, the brand new year 2015 appears quite interesting to me both from the global and also from the local pharmaceutical industry perspective. In this article I shall try to give a glimpse of some of the important drivers … Continue reading
In the Wonderland of Pharma Generics: Some Steps In, Some Steps Over the Line
To scale-up access to healthcare, especially for the marginalized population of any country, greater access to affordable generic drugs will always remain fundamental, besides improving healthcare infrastructure and its delivery mechanism. Thus, there should be a robust mechanism across the … Continue reading